Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 31;144(9):728-745.
doi: 10.1161/CIRCULATIONAHA.120.052163. Epub 2021 Aug 30.

Saphenous Vein Graft Failure: From Pathophysiology to Prevention and Treatment Strategies

Iosif Xenogiannis  1   2 , Marco Zenati  3 , Deepak L Bhatt  4 , Sunil V Rao  5 , Josep Rodés-Cabau  6   7 , Steven Goldman  8 , Kendrick A Shunk  9 , Kreton Mavromatis  10 , Subhash Banerjee  11 , Khaldoon Alaswad  12 , Ilias Nikolakopoulos  1   13 , Evangelia Vemmou  1   13 , Judit Karacsonyi  1 , Dimitrios Alexopoulos  2 , M Nicholas Burke  1 , Vinayak N Bapat  1 , Emmanouil S Brilakis  1
Affiliations
Review

Saphenous Vein Graft Failure: From Pathophysiology to Prevention and Treatment Strategies

Iosif Xenogiannis et al. Circulation. .

Abstract

Saphenous vein grafts (SVGs) remain the most frequently used conduits in coronary artery bypass graft surgery (CABG). Despite advances in surgical techniques and pharmacotherapy, SVG failure rates remain high, often leading to repeat coronary revascularization. The no-touch SVG harvesting technique (minimal graft manipulation with preservation of vasa vasorum and nerves) reduces the risk of SVG failure, whereas the effect of the off-pump technique on SVG patency remains unclear. Use of buffered storage solutions, intraoperative graft flow measurement, careful selection of the target vessels, and physiological assessment of the native coronary circulation before CABG may also reduce the incidence of SVG failure. Perioperative aspirin and high-intensity statin administration are the cornerstones of secondary prevention after CABG. Dual antiplatelet therapy is recommended for off-pump CABG and in patients with a recent acute coronary syndrome. Intermediate (30%-60%) SVG stenoses often progress rapidly. Stenting of intermediate SVG stenoses failed to improve outcomes; hence, treatment focuses on strict control of coronary artery disease risk factors. Redo CABG is associated with higher perioperative mortality compared with percutaneous coronary intervention (PCI); hence, the latter is preferred for most patients requiring repeat revascularization after CABG. SVG PCI is limited by high rates of no-reflow and a high incidence of restenosis during follow-up. Drug-eluting and bare metal stents provide similar long-term outcomes in SVG PCI. Embolic protection devices reduce no-reflow and should be used when feasible. PCI of the corresponding native coronary artery is associated with better short- and long-term outcomes and is preferred over SVG PCI, if technically feasible.

Keywords: coronary artery bypass graft surgery; embolic protection devices; no-reflow; percutaneous coronary intervention; prevention; saphenous vein grafts.

PubMed Disclaimer